Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer
- PMID: 19013709
- DOI: 10.1016/j.canlet.2008.09.037
Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer
Abstract
The resurgent theory of cancer immunosurveillance holds that the immune system plays an important role in the suppression of tumors, particularly in the elimination of early neoplastic lesions. Tumors with reduced immunogenicity or those that have acquired mechanisms to suppress immune effector functions, however, can emerge from this selection pressure and grow progressively. This is an especially important issue in pancreatic cancer, which although inflammatory in vivo is nevertheless highly aggressive and nearly always lethal. Here, we review emerging data obtained from novel genetically defined mouse models of pancreatic adenocarcinoma that suggest that the immune system may be complicit in the inception and progression of pancreatic cancer. Host immune cells with suppressive properties infiltrate the pancreas early during tumorigenesis, even at the earliest stages of neoplasia, preceding and effectively undermining any lymphocytes with potential antitumor function. Thus, in pancreatic adenocarcinoma, the failure of immunosurveillance is likely an early event during tumorigenesis, a concept that carries important implications for the design of novel immunotherapeutics in this disease.
Similar articles
-
Dynamics of the immune reaction to pancreatic cancer from inception to invasion.Cancer Res. 2007 Oct 1;67(19):9518-27. doi: 10.1158/0008-5472.CAN-07-0175. Cancer Res. 2007. PMID: 17909062
-
The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.Cancer Res. 2003 May 1;63(9):2005-9. Cancer Res. 2003. PMID: 12727809
-
Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts.Exp Biol Med (Maywood). 2010 Feb;235(2):263-70. doi: 10.1258/ebm.2009.009215. Exp Biol Med (Maywood). 2010. PMID: 20404043
-
The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.Semin Cancer Biol. 2001 Jun;11(3):201-18. doi: 10.1006/scbi.2000.0371. Semin Cancer Biol. 2001. PMID: 11407945 Review.
-
The immune network in pancreatic cancer development and progression.Oncogene. 2014 Jun 5;33(23):2956-67. doi: 10.1038/onc.2013.257. Epub 2013 Jul 15. Oncogene. 2014. PMID: 23851493 Review.
Cited by
-
Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer.Mol Ther. 2019 Mar 6;27(3):507-517. doi: 10.1016/j.ymthe.2018.11.012. Epub 2018 Nov 17. Mol Ther. 2019. PMID: 30545600 Free PMC article.
-
Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.Cancers (Basel). 2023 Aug 25;15(17):4265. doi: 10.3390/cancers15174265. Cancers (Basel). 2023. PMID: 37686543 Free PMC article. Review.
-
RAS oncogenes: weaving a tumorigenic web.Nat Rev Cancer. 2011 Oct 13;11(11):761-74. doi: 10.1038/nrc3106. Nat Rev Cancer. 2011. PMID: 21993244 Free PMC article. Review.
-
Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12.Mol Oncol. 2011 Jun;5(3):242-55. doi: 10.1016/j.molonc.2011.03.007. Epub 2011 Apr 5. Mol Oncol. 2011. PMID: 21515097 Free PMC article.
-
Metabolism of pancreatic cancer: paving the way to better anticancer strategies.Mol Cancer. 2020 Mar 2;19(1):50. doi: 10.1186/s12943-020-01169-7. Mol Cancer. 2020. PMID: 32122374 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases